Evidence map›Paper›PMID 42265756›Full record

ArticleAmerican journal of hematology2026

CSF ctDNA Molecular Clearance as a Prognostic Biomarker for Orelabrutinib-Treated Primary Central Nervous System Lymphoma: Insights From Comparison With PET-CT.

Lixia Sheng, Huijie Hu, Yanli Lai, Shuyan Wang, Di Wang, Shanhao Tang, Kaihong Xu, Yongcheng Sun, Ping Zhang, Binbin Lai and 7 more

Abstract readComparative StudyLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Lixia ShengDepartment of Hematology, The First Affiliated Hospital of Ningbo University, Ningbo, China.
Huijie HuSchool of Medicine, Ningbo University, Ningbo, China.
Yanli LaiDepartment of Hematology, The First Affiliated Hospital of Ningbo University, Ningbo, China.
Shuyan WangDepartment of Histopathology, Ningbo Clinical Pathology Diagnosis Center, Ningbo, China.
Di WangDepartment of Medical, Nanjing Geneseeq Technology Inc., Nanjing, China.
Shanhao TangDepartment of Hematology, The First Affiliated Hospital of Ningbo University, Ningbo, China.ORCID https://orcid.org/0000-0002-4761-3352
Kaihong XuDepartment of Hematology, The First Affiliated Hospital of Ningbo University, Ningbo, China.
Yongcheng SunDepartment of Hematology, The First Affiliated Hospital of Ningbo University, Ningbo, China.
Ping ZhangDepartment of Hematology, The First Affiliated Hospital of Ningbo University, Ningbo, China.
Binbin LaiDepartment of Hematology, The First Affiliated Hospital of Ningbo University, Ningbo, China.
Li HuDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Ningbo University, Ningbo, China.
Lieguang ChenDepartment of Hematology, The First Affiliated Hospital of Ningbo University, Ningbo, China.
Yuning PanDepartment of Radiology, The First Affiliated Hospital of Ningbo University, Ningbo, China.
Sheng NieDepartment of Neurosurgery, The First Affiliated Hospital of Ningbo University, Ningbo, China.
Xiang GaoDepartment of Neurosurgery, The First Affiliated Hospital of Ningbo University, Ningbo, China.
Lei FanDepartment of Hematology, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Nanjing, China.
Guifang OuyangDepartment of Hematology, The First Affiliated Hospital of Ningbo University, Ningbo, China.ORCID https://orcid.org/0009-0007-7273-5742

Funding

Central Nervous System Drugs Key Laboratory of Sichuan Province 230042-01SZNatural Science Foundation of Ningbo Municipality 2022J210Natural Science Foundation of Ningbo Municipality 2023J017Ningbo Science and Technology Plan Project 2022S032Zhejiang Basic Public Welfare Research Project LBY24H080002
6 · The paper itself

Abstract

This prospective biomarker study evaluated serial CSF ctDNA monitoring in newly diagnosed PCNSL treated with R-MO induction therapy. Mid-treatment ctDNA clearance was significantly associated with complete response and superior progression-free survival, showing stronger predictive value than interim PET-CT in this cohort. These findings support CSF ctDNA clearance as a promising molecular biomarker for early response assessment in PCNSL.

Indexed as

Biomarkers, TumorCentral Nervous System NeoplasmsCirculating Tumor DNALymphomaPositron Emission Tomography Computed TomographyAgedFemaleHumansMaleMiddle AgedPiperidinesPrognosisProspective StudiesPyridinesBiomarkers, TumorCirculating Tumor DNAorelabrutinibPiperidinesPyridinescerebrospinal fluidcirculating tumor DNAprimary central nervous system lymphomaprognostic biomarkerresponse ratesurvival

Identifiers

PMID42265756
PMCPMC13544486

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.